Walmart’s sharp decline highlights growing concern over U.S. consumer resilience, as slower comparable-sales growth and reliance on a one-off tariff refund weakened the quality of its earnings beat. Moderna’s reversal reflects profit-taking after its historic 177% rally, rather than necessarily a change in the underlying cancer-treatment outlook. Meanwhile, rising Treasury yields pressured equities broadly, reinforcing a more cautious risk environment.